Vetr Crowd Says Buy Vertex Pharmaceuticals

Shares of Vertex Pharmaceuticals Incorporated VRTX have lost more than 28 percent year-to-date, even after surging more than 10.6 percent in the last month. Over the past five trading days, shares tumbled almost 5 percent, unlocking some room for upside. Or so the Vetr crowd seem to believe, as evidenced by its average price target of $94.50, which implies a potential return of 4.6 percent from current valuations.

Related Link: Here's How Crowdsourced Ratings Can Beat The Market

Seeking to better reflect this upside potential, the Vetr community decided upgrade its rating on shares of Vertex on Tuesday, from 3.0 Stars (Hold) to 3.5 Stars (Buy) - out of a possible 5.0 Stars rating.

Finally, it should be noted that, while price targets and the corresponding rating are conservative, the crowd is optimistic on the stock as 72 percent of its ratings are bullish.

Disclosure: Javier Hasse holds no positions in any of the securities mentioned above.